Selected assignments

Completed appointments, board to senior executive.

A representative selection across pharmaceuticals, biotechnology, medical devices, genomics and CRO businesses, from pre-revenue spin-outs to top-ten pharma.

Client names are withheld as a matter of course. Turnover figures indicate the scale of the business at the time of appointment.
AppointmentClient
Chief Executive OfficerUK pre-revenue MedTech university spin-out
Chief Medical OfficerPre-revenue UK biotech
Chief Medical OfficerListed CRO, GBP10m turnover
Chief Scientific OfficerPre-revenue UK biotech
Chief Financial OfficerAIM-listed CRO, GBP6m turnover
Chief Financial OfficerAIM-listed CRO, GBP5m turnover
Interim Chief Financial OfficerAIM-listed CRO, GBP58m turnover
Divisional Managing DirectorUS-headquartered CRO, USD40m turnover
EMEA General ManagerUS-headquartered medical devices company, USD2.2bn turnover
Commercial Director, EMEA, APAC & LatAmUK-headquartered MedTech company, GBP110m turnover
VP Sales, EMEAUS-headquartered medical devices company, USD19bn turnover
VP Sales, EMEAUS-headquartered genomics company, USD3bn turnover
VP, Global Business DevelopmentUS-headquartered CRO, USD40m turnover
Business Development Director, EMEAUS-headquartered CRO, USD40m turnover
VP, Clinical Development, CNSUS-headquartered pharmaceutical company, USD16bn turnover
VP Medical Affairs, ImmunologyUS-headquartered pharmaceutical company, USD16bn turnover
VP Medical Affairs, CNSUS-headquartered pharmaceutical company, USD16bn turnover
Global Clinical Lead, Oncology assetTop 10 pharmaceutical company, USD40bn turnover
Global Clinical Lead, CKD assetTop 10 pharmaceutical company, USD40bn turnover
Global HR DirectorJapan-listed pharmaceutical company
Group Financial ControllerPE-backed CRO, GBP30m turnover
Head of FP&AAIM-listed CRO, GBP58m turnover
Non-Executive DirectorAIM-listed biotech, business development background
Non-Executive DirectorPre-revenue biotech, Chief Scientific Officer background
Get in touch

Looking for an appointment like these?

We would be glad to talk through the brief and tell you honestly whether we are the right firm for it.

Start a conversation